Meeting of the Parliament 13 January 2026
The final item of business is a members’ business debate on motion S6M-20160, in the name of Fulton MacGregor, on improving support and treatment for people living with phenylketonuria. The debate will be concluded without any question being put.
I ask members who wish to participate to press their request-to-speak buttons now or as soon as possible, and I invite Fulton MacGregor to open the debate.
Motion debated,
That the Parliament recognises that phenylketonuria (PKU) is a rare, lifelong metabolic disorder in which the body is unable to process the amino acid phenylalanine, leading to a risk of severe and irreversible neurological damage without strict dietary management; acknowledges the significant daily burden placed on individuals and families living with PKU, including the need for constant monitoring and the exclusion of most everyday foods; notes the recent drop-in event hosted in the Scottish Parliament, which highlighted lived experience and current challenges in accessing treatment and support; further notes ongoing UK trials of a home blood phenylalanine monitoring device and the emerging treatment, sepiapterin, both of which offer the potential to improve quality of life; recognises the work of the National Society for Phenylketonuria (NSPKU) in advocating for improved care and access to treatment, and notes the calls on the Scottish Government and NHS Scotland to consider how services for people with PKU can be strengthened to support better long-term outcomes, including in the Coatbridge and Chryston constituency.
17:10Motions, questions or amendments mentioned by their reference code.